Year-end Sale % OFF 
Abstract
Background and AimsBile duct cancer is one of the lethal cancers, presenting difficulties in early diagnosis and limited treatment modalities. Despite current advances in biomarker research, most studies have been performed in Western populations. Therefore, the purpose of this study was to determine a prognostic marker for bile duct cancer, especially in Korean patients, whose incidence of bile duct cancer is high.ResultsComparing cancer and normal bile duct tissue, we identified 29091 differentially expressed genes. CP, SCEL, and MUC16 had positive coefficients with a log2 ratio >1 for advanced T, N stage and perineural invasion cancer tissue. Strong immunohistochemical expression of ceruloplasmin was dominant in tumors with advanced T stage (p>0.999) and perineural invasion (p=0.316).Patients and MethodsWe performed tissue microarray experiment with 79 bile duct cancer tissue samples and 21 normal bile duct tissue samples. Candidate genes that has positive correlation with T, N stage and perineural invasion were drawn with multivariate analysis. Tissue expression of the genes was evaluated with an immunohistochemical study.ConclusionsCeruloplasmin is supposed to be related with advanced T stage and perineural invasion, having a possibility as a candidate prognostic marker for bile duct cancer.
Highlights
Biliary tract cancer is the 10th most common cancer in the United States, and its mortality ranks 5th among all cancers [1]
Ceruloplasmin is supposed to be related with advanced T stage and perineural invasion, having a possibility as a candidate prognostic marker for bile duct cancer
Sixty-three patients (79.7%) had extrahepatic bile duct cancer, and curative resection was performed in 73 patients (92.4%)
Summary
Biliary tract cancer is the 10th most common cancer in the United States, and its mortality ranks 5th among all cancers [1]. The incidence of biliary tract cancer is higher in Eastern than Western populations, and it is the 9th most common cancer in Korea [2]. The actual 5-year survival rate for bile duct cancer after curative resection ranges from 28 to 30.1% [3, 4]. Surgical candidates are few because of difficulties in early diagnosis caused by asymptomatic manifestation, a lack of sensitive biomarkers, and the cancer’s aggressiveness. Treatment modalities for bile duct cancer are limited, because the cancer is refractory to chemotherapy and radiation treatment. Bile duct cancer is one of the lethal cancers, presenting difficulties in early diagnosis and limited treatment modalities. Despite current advances in biomarker research, most studies have been performed in Western populations. The purpose of this study was to determine a prognostic marker for bile duct cancer, especially in Korean patients, whose incidence of bile duct cancer is high
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
